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Abstract 
Review on congenital/neonatal and infant leukemias, 
with data on clinics, pathology, and involved genes. 
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Identity 
Congenital and neonatal leukemias are defined as 
those diagnosed within the first 4 weeks of life. 
Account for <1% of childhood leukemias. 
Infant leukemias are defined as those diagnosed 
within the first year of like. 
Clinics and pathology 
EPIDEMIOLOGY  
Neonatal/congenital leukemia is estimated at 1-5 
cases/million live births (~2 cases per year in the 
UK) (Roberts et al., 2018). 
Infant leukemia is estimated at ~160 cases/year (41 
cases per million) in the United States (Brown et al, 
2019). 
Infant ALL accounts for 2-5% of pediatric ALL 
cases (Pui et al., 1994). 
Infant AML accounts for 6-20% of pediatric AML. 
Data has shown that patients, diagnosed to have a 
leukaemia at age 5 mths and 2 yrs, already had a 
KMT2A/AFF1 (then MLL-AF4) fusion gene in their 
neonatal blood spots/Guthrie cards (Gale et al., 
1997). 
Infant leukaemias have been suspected to have an 
environmental component (Greaves, 1996): 
- Some of the leukaemias known to be often related 
to genotoxic exposure, such as the 11q23 leukaemias 
and the t(8;16) leukaemia, may also be found in 
infants.  
- There has been a significant increase in infant acute 
leukaemias incidence of around 2.5% per year for 15 
yrs, suggesting the presence of an environmental 
factor.  
- Studies have found an increased risk after maternal 
marijuana use and alcohol consumption. 
- Maternal exposure to dietary flavonoids during 
pregnancy may contribute to the risk of KMT2A 
rearranged leukemias. 
- Infants with leukaemia (excluding Down syndrome 
cases) have more congenital anomalies (heart 
defects, digestive tract anomalies, mental delay).  
CLINICS  
Sex ratio is balanced, both in AML and in ALL 
cases. 
Neonatal leukemias:  
 Common to have hepatosplenomegaly (~80% of 
cases), skin lesions (leukemia cutis, ~50% of cases), 
CNS involvement (~50% of cases), and/or 
hyperleukocytosis. 
 Cutaneous involvement can be the presenting 
feature and can manifest as the so-called “blueberry 
muffin baby” appearance with blue, purple, brown, 
or red nodules. 
- 2/3 of AML cases have cutaneous involvement. 
- 1/2 of ALL cases have cutaneous involvement. 
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Anemia, thrombocytopenia, and neutropenia can 
lead to increased bleeding tendency, infections, and 
failure to thrive. 
 Infiltration of the CNS can cause cranial nerve 
palsies, seizures, and papilledema. 
 Meningeal infiltration can manifest as a bulging 
fontanelle. 
Infant leukemias: 
 Many have aggressive features including high WBC 
counts, hepatosplenomegaly, frequent CNS 
involvement, and/or skin infiltrations (leukemia 
cutis). 
PATHOLOGY/CYTOGENETICS 
Neonatal leukemia - 2/3 AML; 1/3 ALL 
Infant leukemia - more likely ALL than AML 
ALL 
 11q23 (KMT2A) gene rearrangements in 70-80% of 
infants and up to 91% of those infants younger than 
6 months (Pieters et al., 2007; Zweidler-McKay and 
Hilden, 2008). 
 Most common KMT2A partners are AFF1, MLLT1, 
MLLT3, and MLLT10 (Pieters et al., 2007). 
 Usually express CD19, CD22, and TdT by flow 
cytometry.  Those without KMT2A fusions usually 
express CD10; those with KMT2A rearrangements 
often lack CD10 but express CD15.  
AML 
 Usually myelomonocytic (FAB M4), 
monoblastic/monocytic (FAB M5), or 
megakaryoblastic leukemia (FAB M7). 
 11q23 (KMT2A) gene rearrangements in 50% of 
infants (Brown et al., 2019; Zweidler-McKay and 
Hilden, 2008). 
 Most common KMT2A partners are MLLT3, 
MLLT10, and ELL (Pieters et al., 2007) 
 Usually express CD13 and CD33 by flow 
cytometry; M4 and M5 also express CD14 and 
CD15; M7 also expresses CD61, CD42b, and/or 
CD41 by flow cytometry. 
TREATMENT  
 ALL Interfant-99 protocol uses a 7-day prednisone 
prophase and then a hybrid regimen of standard ALL 
therapy with some AML therapy elements (including 
cytarabine) (Brown et al., 2019; Pieters et al., 2007).  
 AML Generally treated on the same clinical 
protocols as older children with multiagent 
chemotherapy plus CNS-directed therapy (Brown et 
al., 2019). 
PROGNOSIS  
 ALL 
 4yr event free survival is 47% and 4-year overall 
survival is 55.3% (Pieters et al., 2007). 
- However, 4-year EFS of those with KMT2A 
rearrangements was 37% compared to 74% in those 
without KMT2A rearrangements. 
 High WBC (>300 K/uL), young age (<6 months), 
presence of KMT2A rearrangement, and poor 
prednisone response were significant predictors of 
poor outcome (Pieters et al., 2007). 
 Survival after relapse is low, with 3-year overall 
survival after relapse of 20.9% (Driessen et al., 
2016). 
 In those who relapse, outcome is negatively 
impacted by age at original diagnosis (<6 months of 
age), higher WBC count at diagnosis, and relapse 
within 1 year after diagnosis (Driessen et al., 2016). 
 In those with congenital leukemia, the 2-year EFS 
and OS is 20% (van der Linden et al., 2009).  
 AML  
 Outcomes are similar in infants to those of older 
children with 5-year overall survival of 51% and 5-
year event free survival of 44%. 
 Spontaneous regression/remission can occur in rare 
cases (Bresters et al., 2002; Roberts et al., 2018; van 
den Berg et al., 2004).  
Survivors of infant leukemia demonstrate increased 
risk of late effects including growth problems, 
learning difficulties, hypothyroidism, and pubertal 
development (Roberts et al., 2018).  
Use of hematopoietic stem cell transplantation is 
controversial and findings are not conclusive as to 
whether it improves survival. 
Disease 
Transient abnormal myelopoiesis (TAM) of 
Down syndrome 
Epidemiology 
Restricted to newborns with trisomy 21 or mosaic for 
trisomy 21. 
Clinics 
Some infants (10-25%) are asymptomatic, only 
presenting with increased circulating blasts (Massey 
et al., 2006; Klusmann et al., 2008). Most neonates 
present at 3-7 days of age with a leukocytosis and an 
abnormal platelet count (usually thrombocytopenia, 
but thrombocytosis has also been identified).  
Hepatomegaly is common due to fibrosis and/or 
megakaryoblast infiltration.  Other clinical findings 
include splenomegaly, exudative effusions 
(including pleural, pericardial, and ascites), and 
respiratory distress (due to hepatomegaly). In utero 
presentations include hydrops fetalis and anemia. 
Genes 
GATA1 somatic mutations are present. 
Evolution 
Spontaneous resolution of blasts and symptoms 
occurs in 66-84% of infants over a time period of  
2-3 months without a need for intervention 
(Klusmann et al., 2008; Gamis et al., 2011). The 
remaining infants may need supportive therapy or 
chemotherapy.  Overall, approximately 15-20% of 
cases still die, though some of these are due to other 
abnormalities associated with trisomy 21 (Klusmann 
et al., 2008; Gamis et al., 2011).  Approximately 16-
30% of infants, whether they were asymptomatic or 
had clinical symptoms, develop myeloid leukemia 
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associated with Down syndrome (Klusmann et al., 
2008). 
Disease 
11q23 abnormalities 
Phenotype/cell stem origin 
Acute monoblastic/monocytic or myelomonocytic 
leukaemia (AML) or CD19+ B-cell acute 
lymphoblastic leukaemia (B-ALL). 
Epidemiology 
11q23 (KMT2A) gene rearrangements are in present 
in 70-80% of infants with B-ALL and up to 91% of 
those infants younger than 6 months with B-ALL 
(Pieters et al., 2007).  
11q23 (KMT2A) gene rearrangements are present in 
50% of infants with AML (Brown et al., 2019). 
Clinics 
Organomegaly; frequent CNS involvement; high 
WBC count (Huret et al., 1993; Johansson et al., 
1998). 
Pathology 
In those with ALL and KMT2A gene 
rearrangements, flow cytometry 
immunophenotyping often shows expression of 
CD19, CD22, TdT, and CD15 with absence of 
CD10; CD13 an CD33 may be expressed. 
In those with ALL and KMT2A gene 
rearrangements, there is often overexpression of 
FLT3. 
In those with AML, there is often expression of 
CD13, CD14, CD15, and CD33. 
Prognosis 
4 year event free survival is 37% (Pieters et al., 
2007).  
t(4;11)(q21;q23) KMT2A/AFF1: may have worse 
outcome (Heerema et al., 1994) 
Cytogenetics 
 t(4;11)(q21;q23) KMT2A/AFF1 : most common 
infant translocation; usually ALL (49% of B-ALL 
cases, and more often in those <6 months of age), but 
can be AML (<5%) (acute monoblastic/monocytic or 
myelomonocytic leukemia), or mixed phenotype 
acute leukemia (Johansson, et al., 1998). 
 
 
t(9;11)(p23;q23) KMT2A/MLLT3 : found in 22% 
infant acute monoblastic/monocytic or 
myelomonocytic AML and 17% of infant ALL 
(Köller et al., 1989; Swansbury et al., 1998). 
 t(10;11)(p12;q23) KMT2A/MLLT10 : found in 
27% infant acute monoblastic/monocytic or 
myelomonocytic AML and 5% of infant ALL 
(Lillington et al., 1998). 
 t(11;19)(q23;p13.3) KMT2A/MLLT1: found in 
22% infant ALL, mixed phenotype acute leukemia, 
and 15% acute monoblastic/monocytic or 
myelomonocytic leukemia (Huret et al., 1993; 
Moorman et al., 1998). 
 t(11;19)(q23;p13.1) KMT2A-ELL: found in 17% 
AML, usually acute myelomonocytic or 
monoblastic/monocytic leukemia (Moorman et al., 
1998). 
 other 11q23 rearrangements are rarely found in 
infants leukemias. 
Disease 
t(1;22)(p13;q13) RBM15/MKL1 
Phenotype/cell stem origin 
Acute megakaryoblastic leukemia (M7 AML). 
Note 
This is a cryptic fusion not identified by routine 
karyotyping, and usually requiring RNA sequencing 
for identification. 
Epidemiology 
This leukaemia is (nearly) restricted to infant cases; 
median age is 2-4 months (Bernstein et al., 1999; 
Chan et al., 1991; Lion and Haas, 1993); accounts 
for <1% AML. 
Clinics 
Organomegaly, liver and bone marrow fibrosis. 
Prognosis 
Remission is obtained in only half cases, median 
survival is 8 months (Bernstein et al., 1999). 
Disease 
AMkL with inv(16)(p13q24) CBFA2T3/GLIS2 
Phenotype/cell stem origin 
Acute megakaryoblastic leukemia in most cases, 
though rare other AML subtypes are identified with 
this fusion. 
Epidemiology 
Usually presents in infants (Bolouri et al., 2017; 
Hara et al., 2017). 
Prognosis 
Poor prognosis with 4-5-year OS ranging from 14-
41.7% and 4-5-year EFS ranging from 8-33% (de 
Rooij et al., 2016; de Rooij et al., 2017; Hara et al., 
2017). 
 
Disease 
AML with t(11;12)(p15;p13) NUP98/KDM5A 
Phenotype/cell stem origin 
Acute megakaryoblastic leukemia in most cases, 
though rare other AML subtypes are identified with 
this fusion. 
Epidemiology 
Can present in infants (de Rooij et al., 2016). 
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Prognosis 
Usually a poor prognosis with 4-5-year OS ranging 
from 22-50% and 4-5-year EFS ranging from 22-
36% (de Rooij et al., 2013; de Rooij et al., 2016; de 
Rooij et al., 2017; Hara et al., 2017). 
Disease 
inv(16)(p13q22) 
Phenotype/cell stem origin 
Myelomonocytic leukemia (M4 AML) 
Epidemiology 
At least 3 cases reported. 
Clinics 
High WBC, CNS involvement in 2/3 (Pui et al., 
1987). 
Disease 
t(5;15)(p15;q11) 
Phenotype/cell stem origin 
B lineage ALL 
Epidemiology 
5 known cases (Heerema et al., 1994). 
Prognosis 
unknown; CR in 5/5. 
Disease 
t(8;16)(p11;p13) KAT6A/CREBBP 
Phenotype/cell stem origin 
Acute myelomonocytic or monoblastic/monocytic 
AML. 
Clinics 
Leukemia cutis, hepatosplenomegaly. 
Prognosis 
Has shown spontaneous regression in some cases, 
though some do relapse (Dinulos et al., 1997; 
Roberts et al., 2018) Other cases require 
chemotherapy from diagnosis. 
Disease 
Juvenile myelomonocytic leukemia 
Epidemiology 
Annual incidence is approximately 0.67 
cases/million with a median age of 1.1-1.8 years and 
male to female ratio of 2-3:1. (Hasle et al.,  
1999; Niemeyer et al., 1997; Passmore et al., 2003). 
Clinics 
Splenomegaly, lymphadenopathy, and skin rashes 
are common (Hess et al., 1996).  
The diagnostic criteria for JMML are (Locatelli and 
Neimeyer, 2015; Baumann, et al., 2017).  
 Clinical and hematologic features (all 4 required) 
 Peripheral blood monocyte count ≥1 x 109/L. 
 Peripheral blood and bone marrow blast percentages 
<20%. 
 Splenomegaly. 
 No Philadelphia (Ph) chromosome or BCR/ABL1 
fusion. 
 Genetic criteria (1 finding is sufficient) 
 Somatic mutation in PTPN11, KRAS, or NRAS. 
 Clinical diagnosis of neurofibromastosis type 1 or 
NF1 mutation. 
 Germline CBL mutation and loss of heterozygosity 
of CBL. 
 Other criteria (those not meeting genetic criteria 
but having clinical and hematologic criteria must 
also have). 
 Monosomy 7 or any other chromosomal 
abnormality. 
 or ≥ 2 of the following:  
 Increased hemoglobin F (HbF) for age. 
 Myeloid or erythroid precursors on peripheral blood 
smear. 
 Granulocyte-macrophages colony-stimulating 
factor (GM-CSF) hypersensitivity in colony assay. 
 Hyperphosphorylation of STAT5. 
Prognosis 
Those with germline mutations in PTPN11, KRAS, 
NRAS, or CBL have disease that may spontaneously 
regress without therapy (Locatelli and Neimeyer, 
2015).   
However, in other cases HSCT is recommended, 
after which the 5-year overall survival rate is 64%, 
with an event free survival of 52% (Locatelli et al., 
2005). 
Genes involved and 
proteins 
KMT2A (MLL) 
Location 
11q23 
DNA/RNA 
Encodes a histone-lysine N-methyltransferase, a 431 
kDa protein; contains 3 AT hook DNA-binding 
domains, Zinc fingers, a SET domain which is 
responsible for its DNA methyltransferase activity, 
and a bromodomain. 
Protein 
Regulates gene expression during early development 
and hematopoiesis; regulates transcription of many 
target genes, including HOX genes.  
The fusion proteins usually include the N-terminus 
AT hook and DNA methyltransferase from KMT2A 
fused to (little or most of) the partner C-term part 
from the other chromosome. 
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